Tandem Diabetes Care (TNDM) Accounts Payables (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported Accounts Payables for 14 consecutive years, with $64.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables rose 14.85% year-over-year to $64.1 million; the trailing twelve-month figure through Jun 2026 stood at $64.1 million (up 14.85% YoY), and the FY2025 full-year result was $47.1 million, up 5.22% from the prior year.
• Accounts Payables climbed to $64.1 million in Q2 2026 per TNDM's latest filing, from $59.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $64.1 million in Q2 2026 and bottomed at $44.7 million in Q4 2024.
• Historically, Accounts Payables has averaged $52.5 million across 5 years, with a median of $50.1 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables surged 128.12% in 2022, then slipped 25.01% in 2023.
• Over 5 years, Accounts Payables stood at $55.7 million in 2022, then dropped by 11.02% to $49.6 million in 2023, then dropped by 9.79% to $44.7 million in 2024, then climbed by 5.22% to $47.1 million in 2025, then jumped by 36.25% to $64.1 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $64.1 million, $59.9 million, and $47.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.